Clinical Trials


Broward Health's clinical trials program focuses on finding better ways to treat illnesses through a voluntary program between patients and their doctors. A clinical trial is a research study where individuals receive investigational treatments under the supervision of a physician and other research professionals.

Clinical Trials

Broward Health's clinical trials program focuses on finding better ways to treat illnesses through a voluntary program between patients and their doctors. A clinical trial is a research study where individuals receive investigational treatments under the supervision of a physician and other research professionals.

What Are Clinical Trials?

Broward Health has a variety of Active Adult and Pediatric Clinical Trials available on a continual basis, which may include medical research using investigational devices or participation in a clinical drug trial for the treatment of heart disease, cancer, HIV/AIDS, memory disorders, traumatic brain injury, and other diseases.

Clinical trials are studies in which people volunteer to take part in tests of new drugs or procedures. Doctors use clinical trials to develop new treatments for serious diseases, such as cancer. For those individuals who do participate in a clinical trial, they may have an opportunity to benefit from a new treatment that not might otherwise have been known. You may learn more about clinical trials by visiting ClinicalTrials.gov.

Current Studies at Broward Health

Clinical trials are studies in which people volunteer to take part in tests of new drugs or procedures. Doctors use clinical trials to develop new treatments for serious diseases, such as cancer or cardiovascular disease. You may learn more about clinical trials by visiting ClinicalTrials.gov

PEDIATRIC CANCER TRIALS 

  • Leukemia
    • AAML1531: A Children’s Oncology Protocol for Phase III, Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
    • AALL1331: A Children’s Oncology Protocol for Blinatumomab in Treating Younger Patients with Relapsed B-cell Acute Leukemia
    • AALL1631: A Children’s Oncology Protocol for an International Phase III Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Ph+ ALL Testing Imatinib in Combination with Two Different Cytotoxic Chemotherapy Backbone   
  • Neuroblastoma
    • ANBL00B1: A Children’s Oncology Group Protocol for Biomarkers in Tumor Tissue Samples from Patients with Newly Diangosed Neuroblastoma or Ganglioneuroblastoma
    • ANBL1232: A Children’s Oncology Group Protocol for Response and Biology-Based Risk Factor Guided Therapy in Treating Younger Patients with Non-High Risk Neuroblastoma
  • Renal/Kidney
    • AREN03B2: A Children’s Oncology Group Protocol for Study of Kidney Tumors in Younger Patient 
  • Other
    • ALTE05N1: A Children’s Oncology Protocol for Long-Term Follow-Up of Patients Who Have Participated in COG Studies
    • APEC1621: A Children's Oncology Protocol for MATCH (Molecular Analysis for Therapy Choice) Examining Molecular Changes Using Genomic Sequencing Technologies in Refractory/Recurrent Tumors in Children and Adolescents
    • APEC1621C: A Children's Oncology Protocol for MATCH (Molecular Analysis for Therapy Choice) for the Screening of Children and Adolescents
    • APEC14B1: A Children’s Oncology Protocol for Project: EveryChild: A Registry, Eligibility Screening, Biology, and Outcome Study

PEDIATRIC SICKLE CELL DISEASE

  • Sickle Cell Disease
    • Hestia3: A Randomized Double-Blind Parallel Group Multi-Centre Phase III Study to Evaluate the Effect of Ticagrelor versus Placebo in Reducing the Rate of Vaso-Occlusive Crises in Pediatric Patients with Sickle Cell Disease 

PEDIATRIC HIV DISEASE

  • HIV
    • IMPAACT P1093 V5.0: A Phase I/II, Multi-Center Open-Label Pharmacokinetic Safety Tolerability and Antiviral Activity of Dolutegravir, A Novel Integrase Inhibitor, In Combination Regiments in HIV-1 Infected Infants, Children, and Adolescents
    • IMPAACT P1110 V2.0: A Phase I Trial to Evaluate the Safety and Pharmacokinetics of Raltegravir in HIV-1 Exposed Neonates at Risk of Acquiring HIV-1 Infections
    • IMPAACT P1112 V4.0: An Open-Label Dose-Escalating Phase I Study to Determine Safety and Pharmacokinetic Parameters of Subcutaneous (SC) VRC01, VRC01LS, and VRC07-523LS, Potent Anti-HIV Neutralizing Monoclonal Antibodies, in HIV-1 Exposed Infants
    • IMPAACT P1115 V2.0: A Very Early Intensive Treatment of HIV-1 Infected Infants to Achieve HIV Remission: A Phase I/II Proff of Concept Study
    • IMPAACT P2008 V2.0: A Phase I/II, Multi-Site Randomized Controlled Study of Monoclonal Antibody VRC01 with Combination Antiretroviral Therapy to Promote Clearance of HIV-1 Infected Cells in Infants
    • PH100 SMARTT V5.0: PHACS 100: Surveillance Monitoring for ART Toxicities in HIV Uninfected Children Born to HIV Infected Women (SMARTT Study). Version Change Includes SMARTT Reference Cohort Sub Study and SMARTT Nutrition Sub Study

YOUTH AND YOUNG ADULT HIV DISEASE

  • HIV
    • IMPAACT 2002 V1.0: Combined Cognitive Behavioral Therapy and a Medication Management Algorithm for Treatment of Depression Among Youth Living with HIV in the United States
    • PH300 AMP Up V1.0: PH300: A Multi-Center Study of the Pediatric HIV/AIDS Cohort Study (PHACS), Adolescent Master Protocol for Participants 18 Years of Age and Older (AMP Up) Version 1.0
    • PH204 AMP Oral Health Follow Up Study V1.0: A Re-Examination of Oral Health Among Participants in PHACS Adolescent Master Protocol (AMP-PH200) and Adolescent Master Protocol for Participants 18 Years of Age and Older (AMP Up-PH300)
    • ATN 152 V1.4: Triggered Escalating Real-time Adherence Intervention to Promote Rapid HIV Viral Suppression Among Youth Living with HIV Failing First Line Antiretroviral Therapy: The TERA Study
    • IMPAACT 2017 V2.0: Phase I/II Study of the Safety, Acceptability, Tolerability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Long-Acting Injectable Rilpivirine in Virologically Suppressed HIV Infected Children and Adolescents - MOCHA More Options for Children and Adolescents

ADULT CANCER RESEARCH TRIALS

  • Lung
    • Alliance A221504: A Randomized Double-Blind Placebo Controlled Pilot of an Oral Selective Peripheral Opioid Receptor Antagonist in Advanced Non-Small Cell Lung Cancer (Adenocarcinoma)
    • EA5161: A Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination with Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)
  • Breast
    • Alliance A011401: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
    • Alliance A011502: Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial
    • CCTG MA.39: Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
    • SWOG S1207: A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Hemotherapy in Patients Hormone Receptor-Positive and HER2-Negative Breast Cancer
    • SWOG S1501: Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic Her2+ Breast Cancer
    • SWOG S1703: Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive Breast Cancer
    • NSABP B-55/BIG 6-13: Randomized Double-Blind Parallel Group Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA 1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
  • Colon 
    • Alliance A021502: A Randomized Trial of Standard Chemotherapy Alone or Combined wtih Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
  • MT Group: Translational Medicine: Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized Management of Patients
    • MT0217: Non-Small Cell Lung Cancer (NSCLC)
    • MT0027: Colon Cancer
    • MT0033: Melanoma or Non-Small Cell Lung Cancer
    • MT0270: Renal Cell Carcinoma (RCC)
    • MT Group Fresh Tissue Request

CARDIOVASCULAR RESEARCH

  • Topera: Randomized Evaluation of Redo Ablation Procedures of Atrial Fibrillation With Focal Impulse and Rotor Modulation Guided Procedures (REDO-FIRM)
  • St. Jude AMPLATZER™ Amulet™: Left Atrial Appendage (LAA) Occluder Trial (Amulet IDE)
  • CONNECT - HF: Care Optimization Through Patient and Hospital Engagement Clinical Trial for Heart Failure

Contact Us

Email Icon Email: BHResearch@browardhealth.org

Phone Icon Phone: 954-712-2983

Find a Doctor

We can match you to a doctor based on your location, language preference, and more. The search results will provide more ways to narrow your search.

Available At